Skip to main content
      RT @RichardPAConway: Who would have thought red cells would be so important in SLE? #ACR21 @RheumNow https://t.co/qnPuZU

      Richard Conway RichardPAConway

      4 years ago
      Who would have thought red cells would be so important in SLE? #ACR21 @RheumNow https://t.co/qnPuZUmEjh
      RT @KDAO2011: NETosing is now a verb!

      Dr. Brenner: #BasicScience #YearinReview #ACR21
      IFN sig driven by:
      👉nucleic a

      TheDaoIndex KDAO2011

      4 years ago
      NETosing is now a verb! Dr. Brenner: #BasicScience #YearinReview #ACR21 IFN sig driven by: 👉nucleic acid from PMNs NETosing 👉IC's containing Ab and nucleic acid 👉pDC's recog nucleic acids, produce type I IFN risk alleles 👉Erythroid mitochondrial retention👈 @RheumNow https://t.co/dsNRj7oSBK
      RT @Janetbirdope: OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA

      Janet Pope Janetbirdope

      4 years ago
      OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27
      RT @Yuz6Yusof: #ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their mitochondria (Mito+ RBCs) and their frequency correlated with disease activity and blood⬆️IFN @RheumNow https://t.co/ZixgAbOWJ0 https://t.co/hkTWE4m7Ph
      RT @ericdeinmd: ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparin

      Eric Dein ericdeinmd

      4 years ago
      ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8
      RT @RHEUMarampa: #ACR21 #YearinReview
      Avacopan: The game changer for ANCA #vasculitis?🧐
      🔅Remission at wk 26: Avaco

      sheila RHEUMarampa

      4 years ago
      #ACR21 #YearinReview Avacopan: The game changer for ANCA #vasculitis?🧐 🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001) 🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001) @RheumNow https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
      RT @KDAO2011: 👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side ef

      TheDaoIndex KDAO2011

      4 years ago
      👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21 Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
      RT @KDAO2011: Dr. K Costenbader #ACR21 #YearinReview add-ons Rx:
      👉Avacopan for AAV: new oral C5a inh allowed for remi

      TheDaoIndex KDAO2011

      4 years ago
      Dr. K Costenbader #ACR21 #YearinReview add-ons Rx: 👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ
      RT @ericdeinmd: AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active l

      Eric Dein ericdeinmd

      4 years ago
      AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active lupus nephritis, very positive data @rheumnow #ACR21 https://t.co/rudYD1OC59
      RT @ericdeinmd: Year in Review #ACR21. How do you feel about JAK inhibitor after one year of new studies and the new FDA

      Eric Dein ericdeinmd

      4 years ago
      Year in Review #ACR21. How do you feel about JAK inhibitor after one year of new studies and the new FDA warning? @Rheumnow
      RT @Janetbirdope: #ClinicalPearl #JAKi works in #ankylosingspondylitis (AS). Trial of #tofacitinib positive. Don’t con

      Janet Pope Janetbirdope

      4 years ago
      #ClinicalPearl #JAKi works in #ankylosingspondylitis (AS). Trial of #tofacitinib positive. Don’t confuse with jack ass! @YearinReview #ACR21 @RheumNow presented by Karen Costenbader https://t.co/2VvEMhiI8L
      RT @ericdeinmd: #ACR21 Year in Review: Stepped Exercise program for knee OA - decrease in pain and increase in function,

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Year in Review: Stepped Exercise program for knee OA - decrease in pain and increase in function, without objective measures showing improvement. Time to prescribe exercise! @Rheumnow https://t.co/LrNZ3pBO9i
      RT @bella_mehta: How to improve clinical care for knee OA? stepped exercise program helps WOMAC self reported pain outco

      Bella Mehta bella_mehta

      4 years ago
      How to improve clinical care for knee OA? stepped exercise program helps WOMAC self reported pain outcomes in Knee OA Important RCT #ACR21 year in review by @karen_kc123 @RheumNow @AnnalsofIM here is a paper https://t.co/RGIjBL9TuZ
      RT @CCalabreseDO: Join us tomorrow at #ACR21 in the #COVID19 hub at 12p EST where I’ll be discussing outpatient manage

      Cassandra Calabrese CCalabreseDO

      4 years ago
      Join us tomorrow at #ACR21 in the #COVID19 hub at 12p EST where I’ll be discussing outpatient management of high risk covid patients with @LCalabreseDO #mAbs @philipcrobinson @ACRheum https://t.co/LkSw48cnWw
      ×